These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25228365)

  • 1. High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.
    Stone E; Allen HA; Saghaie T; Abbott A; Daniel R; Mead RS; Kohonen-Corish M; Plit M; Morgan L
    Intern Med J; 2014 Dec; 44(12a):1188-92. PubMed ID: 25228365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
    Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
    Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
    Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
    Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
    Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.
    Takenaka T; Takenoyama M; Yamaguchi M; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Yoshida T; Shiraishi Y; Morodomi Y; Hirai F; Taguchi K; Shimokawa M; Seto T; Ichinose Y
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):550-5. PubMed ID: 24894095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
    Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
    Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
    J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.
    Weber B; Hager H; Sorensen BS; McCulloch T; Mellemgaard A; Khalil AA; Nexo E; Meldgaard P
    Lung Cancer; 2014 Feb; 83(2):224-30. PubMed ID: 24388704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
    Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
    Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
    Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
    Koyama N; Uchida Y
    Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
    Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.
    Okami J; Taniguchi K; Higashiyama M; Maeda J; Oda K; Orita N; Koizumi K; Kodama K; Kato K
    Oncology; 2007; 72(3-4):234-42. PubMed ID: 18176089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.